BAT-200

BAT-200 is a preclinical-stage small molecule antifungal candidate developed by **Bright Angel Therapeutics** (a subsidiary of **Schrödinger**) for the treatment of **invasive fungal infections**, including those caused by drug-resistant pathogens. The program is part of a pipeline focused on identifying and targeting fungal-specific vulnerabilities, such as stress response pathways, to overcome the limitations of current antifungal classes like azoles, echincandins, and polyenes. While the company's lead program, BAT-100, is a fungal-selective Hsp90 inhibitor, BAT-200 targets a distinct, undisclosed essential fungal mechanism. The development of BAT-200 aims to provide a novel therapeutic option for life-threatening infections such as candidemia and invasive aspergillosis, which are associated with high mortality rates in immunocompromised populations.